Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6828339 | SYNTHON PHARMS | Amlodipine salt forms and processes for preparing them |
Nov, 2022
(2 months ago) |
Market Authorisation Date: 27 September, 2007
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(18 years from now) | |
US11458095 | CMP DEV LLC | NA |
Feb, 2041
(18 years from now) |
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable angina; Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina
Dosage: SOLUTION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic